Developer docs
API playgroundTry for free, no card

Search company profiles

SSR Health

Full company profile

uuid00esdlj

Namestring
SSR Health
Legal namestring
SSR Health LLC
Websiteurl
ssrhealth.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

SSR Health LLC is a US-based, privately held data and analytics company founded in 2009 by Dr. Richard Evans that specializes in prescription brand drug pricing intelligence. Its core offering is a proprietary net price database covering approximately 1,000 US brand name prescription drugs across more than 100 companies on a quarterly basis since 2007, delivered through a customizable Tableau Online platform. The company also operates the IRA Selection Tool, a probabilistic prediction framework that models drug-level selection odds for the Inflation Reduction Act's Drug Price Negotiation Program across at least three IPAY forecast horizons, grounded in 100% Part D and Part B CMS spending files.

The firm's revenue model is built on quote-based annual enterprise subscriptions supplemented by individual quarterly report purchases, with all sales routed through a direct engagement model managed by a four-person team that includes the founder/GM, a healthcare economist heading new product development, an analyst responsible for pricing and R&D modeling, and a sales head. Customers span four primary segments: pharmaceutical brand manufacturers, academic and research institutions, federal and state policymakers, and pharmaceutical trade associations. Marketing relies primarily on earned media and academic citations rather than paid acquisition, with SSR Health data and commentary regularly appearing in STAT News, Bloomberg, the Wall Street Journal, JAMA, and Health Affairs.

SSR Health operates as an unfunded, founder-owned LLC with no disclosed institutional investors, no parent company, and no acquisition history. Its competitive position rests on the longitudinal proprietary dataset, the exclusive integration of full CMS Part D and Part B spending files, the IRA-specific probabilistic methodology, and the domain credibility of its principals, who combine buy-side equity research pedigree with applied health economics consulting experience. The company currently serves only the US market, with no international footprint or app distribution channels.

Short descriptiontext

SSR Health LLC is a privately held US data and analytics company founded in 2009 that provides proprietary prescription brand drug pricing data and IRA selection probability forecasts to pharmaceutical manufacturers, policymakers, academics, and trade associations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
Markets served

Serves global market

Keyword5 values
pharmaceutical pricing analytics, drug pricing data, prescription drug analytics, healthcare pricing intelligence, pharma market data
Industry3 codes
PRIMARYHLAIAKAA
Pricing & Contracting Strategy
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Market Access and Pricing
SECONDARYFSAIAGAJ
Medicare Quality, Risk Adjustment & Stars Analytics/Services
Financial & Insurance/Insurance — Life & Health/Medicare Advantage & Medicare Supplement (Medigap)
SECONDARYHLACAKAL
Medication Analytics, Outcomes & Cost Optimization
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT
NAICS code2 codes
  • Marketing Research and Public Opinion Polling541910
  • Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds524292
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Pharmaceutical Pricing Analytics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Data Subscription Access
TypeSubscription Recurring
Description

Subscription-based access to proprietary net pricing database through web-based interface, providing standardized analyses and customized reporting capabilities.

ssrhealth.com
2Individual Report Purchases
TypeSubscription Recurring
Description

Individual report purchases for specific quarterly reports and specialized analysis products. Reports are delivered in PDF format within 24 hours of request.

ssrhealth.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components1 value
Personnel
Pricing details1 tier
1Enterprise subscription with full database access and customized analyses
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based pricing for enterprise-level subscription access to proprietary database, Tableau Online platform analyses, and quarterly reports.

ssrhealth.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

SSR Health provides US prescription brand drug pricing data and analytics through two primary products: the US Prescription Brand Net Pricing Data Tool, which delivers quarterly gross and estimated net pricing data since 2007 for approximately 1,000 products across 100+ companies, and the IRA Selection Tool, which uses a proprietary probabilistic prediction framework built on 100% CMS Part D and Part B spending files to forecast drug-level odds of selection under the Medicare Drug Price Negotiation Program. Both products are delivered through a Tableau Online web-based interface, complemented by quarterly pricing trend reports and regulatory/political impact analyses.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Coverage of approximately 1,000 brand name prescription drugs across more than 100 companies
+1 more record
Product overview1 text field

SSR Health offers a unified platform comprising two primary products: the US Prescription Brand Net Pricing Data Tool and the IRA Selection Tool. The Net Pricing Data Tool delivers quarterly gross and net pricing analytics for approximately 1,000 US brand name prescription drugs across 100+ companies via a Tableau Online interface, while the IRA Selection Tool provides probabilistic predictions for Medicare drug price negotiation selection. Supporting modules include quarterly pricing trend reports and regulatory impact analysis.

Product and service4 records
1IRA Selection Tool
CategoryDrug pricing analytics software
Description

Web-based tool that provides drug-level probabilities of selection for the IRA Drug Price Negotiation Program, including historical changes in those probabilities and quarterly updates to incorporate new policies, guidance, and drug-specific events and sales dynamics. Driven by a proprietary probabilistic prediction framework informed by 100% CMS Part D and Part B spending files, using a bootstrapped model based on a census of Medicare lifecycles. Designed for pharmaceutical brand manufacturers, policymakers, and trade associations assessing direct and indirect IRA impacts.

2US Prescription Brand Net Pricing Data Tool
CategoryPharmaceutical pricing data subscription
Description

Web-based platform that incorporates quarterly gross and estimated net pricing data and trends since 2007 for every quarter going forward, covering approximately 1,000 active US brand name prescription drugs across more than 100 companies. Includes WAC-to-net concessions, Medicaid versus non-Medicaid concessions, product roll-up to industry, therapeutic area, and company levels, and both WAC and net prices by year or course of therapy. Delivered via a Tableau Online interface with standardized and customized analyses for manufacturers, trade associations, policymakers, and academic researchers.

3Quarterly Pricing Trend Reports
CategoryAnalytical report
Description

Individual quarterly reports identifying and assessing positive and negative drivers — by company, therapeutic area, and product — of aggregate net pricing trends, as well as factors influencing pharma market dynamics such as co-pay accumulators and formulary exclusions. Delivered in PDF format within 24 hours of purchase.

4US Political and Regulatory Analysis
CategoryRegulatory analysis report
Description

Standalone analyses of new and proposed legislation and directives — including the Prescription Drug Pricing Reduction Act (PDPRA), International Pricing Index, Anti-Kickback Statute (AKS) safe harbor rule, and the Inflation Reduction Act — and their industry impact on products, segments, and companies. Available as individual report purchases.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Optum's health analytics and research divisions provide large-scale claims, prescription, and pricing data to pharma and policymakers. While far broader in scope, it overlaps with SSR Health's Medicare Part D/B spending analysis and policy impact use cases.

TypeEmerging player
Description

Drug Channels Institute, founded by Adam Fein, produces influential research and analysis on pharmaceutical pricing, distribution, and rebate dynamics. Its content and insights overlap with SSR Health's thought leadership on gross-to-net pricing and market dynamics.

TypeEmerging player
Description

Numerof & Associates is a healthcare strategy consulting firm that helps pharma manufacturers with pricing, market access, and policy impact analysis. It serves a comparable buyer base and addresses overlapping problems with SSR Health's regulatory impact analytics.

TypeDirect peer
Description

Norstella owns EvaluatePharma and other pharma market intelligence assets that forecast drug sales, pricing, and market access dynamics. Both SSR Health and Norstella serve pharma manufacturers with forecasting and pricing intelligence, though SSR Health is more narrowly focused on net pricing and IRA selection probabilities.

TypeDirect peer
Description

Simon-Kucher is a global consulting firm specializing in pricing, monetization, and market access strategy, with deep pharma pricing expertise. It competes with SSR Health's value proposition of helping manufacturers optimize gross-to-net pricing and contracting.

TypeBroad incumbent
Description

Wolters Kluwer offers pharma regulatory and drug-pricing reference data products used by manufacturers and policymakers, comparable to SSR Health's regulatory analysis and pricing data offerings, but as part of a much broader professional information portfolio.

TypeBroad incumbent
Description

IQVIA is the largest global healthcare data and analytics company, offering prescription and commercial datasets (e.g., Xponent, DDD) that overlap with SSR Health's US brand pricing analytics, though IQVIA serves a much broader portfolio of pharma customers.

8ZS Associates
TypeDirect peer
Description

ZS Associates is a consulting firm with a dedicated pharma pricing, market access, and analytics practice serving brand manufacturers. It overlaps with SSR Health's customer base and use cases around gross-to-net pricing strategy and contracting analytics.

TypeDirect peer
Description

Definitive Healthcare provides commercial intelligence for the healthcare and life sciences industry, including prescription and provider data used for market access decisions. It serves a similar set of manufacturer and consulting buyers as SSR Health.

TypeDirect peer
Description

Cencora's consulting arm (formerly Xcenda) provides pharma pricing, market access, and reimbursement analytics to manufacturers, overlapping directly with SSR Health's gross-to-net pricing and policy impact offerings.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SSR Health

Pharmaceutical Pricing Analyticsssrhealth.com

SSR Health LLC is a privately held US data and analytics company founded in 2009 that provides proprietary prescription brand drug pricing data and IRA selection probability forecasts to pharmaceutical manufacturers, policymakers, academics, and trade associations.

What SSR Health does

SSR Health LLC is a US-based, privately held data and analytics company founded in 2009 by Dr. Richard Evans that specializes in prescription brand drug pricing intelligence. Its core offering is a proprietary net price database covering approximately 1,000 US brand name prescription drugs across more than 100 companies on a quarterly basis since 2007, delivered through a customizable Tableau Online platform. The company also operates the IRA Selection Tool, a probabilistic prediction framework that models drug-level selection odds for the Inflation Reduction Act's Drug Price Negotiation Program across at least three IPAY forecast horizons, grounded in 100% Part D and Part B CMS spending files.

The firm's revenue model is built on quote-based annual enterprise subscriptions supplemented by individual quarterly report purchases, with all sales routed through a direct engagement model managed by a four-person team that includes the founder/GM, a healthcare economist heading new product development, an analyst responsible for pricing and R&D modeling, and a sales head. Customers span four primary segments: pharmaceutical brand manufacturers, academic and research institutions, federal and state policymakers, and pharmaceutical trade associations. Marketing relies primarily on earned media and academic citations rather than paid acquisition, with SSR Health data and commentary regularly appearing in STAT News, Bloomberg, the Wall Street Journal, JAMA, and Health Affairs.

SSR Health operates as an unfunded, founder-owned LLC with no disclosed institutional investors, no parent company, and no acquisition history. Its competitive position rests on the longitudinal proprietary dataset, the exclusive integration of full CMS Part D and Part B spending files, the IRA-specific probabilistic methodology, and the domain credibility of its principals, who combine buy-side equity research pedigree with applied health economics consulting experience. The company currently serves only the US market, with no international footprint or app distribution channels.

SSR Health firmographics

Firmographics
Name
SSR Health
Legal name
SSR Health LLC
Website
https://ssrhealth.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
1–10 employees
Short description
SSR Health LLC is a privately held US data and analytics company founded in 2009 that provides proprietary prescription brand drug pricing data and IRA selection probability forecasts to pharmaceutical manufacturers, policymakers, academics, and trade associations.
Ownership category
akta.pro rank

SSR Health industry classification

Industry
Product category
Pharmaceutical Pricing Analytics
NAICS
Marketing Research and Public Opinion Polling (541910), Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds (524292)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAIAKAA
Pricing & Contracting Strategy
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Market Access and Pricing
SECONDARYFSAIAGAJ
Medicare Quality, Risk Adjustment & Stars Analytics/Services
Financial & Insurance/Insurance — Life & Health/Medicare Advantage & Medicare Supplement (Medigap)
SECONDARYHLACAKAL
Medication Analytics, Outcomes & Cost Optimization
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT

Keywords

  • Pharmaceutical pricing analytics
  • Drug pricing data
  • Prescription drug analytics
  • Healthcare pricing intelligence
  • Pharma market data

SSR Health business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel

Revenue model

  1. Data Subscription Access: Subscription-based access to proprietary net pricing database through web-based interface, providing standardized analyses and customized reporting capabilities.
  2. Individual Report Purchases: Individual report purchases for specific quarterly reports and specialized analysis products. Reports are delivered in PDF format within 24 hours of request.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise subscription with full database access and customized analyses

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

SSR Health product offering

Product offering

Core offering

SSR Health provides US prescription brand drug pricing data and analytics through two primary products: the US Prescription Brand Net Pricing Data Tool, which delivers quarterly gross and estimated net pricing data since 2007 for approximately 1,000 products across 100+ companies, and the IRA Selection Tool, which uses a proprietary probabilistic prediction framework built on 100% CMS Part D and Part B spending files to forecast drug-level odds of selection under the Medicare Drug Price Negotiation Program. Both products are delivered through a Tableau Online web-based interface, complemented by quarterly pricing trend reports and regulatory/political impact analyses.

Product overview

SSR Health offers a unified platform comprising two primary products: the US Prescription Brand Net Pricing Data Tool and the IRA Selection Tool. The Net Pricing Data Tool delivers quarterly gross and net pricing analytics for approximately 1,000 US brand name prescription drugs across 100+ companies via a Tableau Online interface, while the IRA Selection Tool provides probabilistic predictions for Medicare drug price negotiation selection. Supporting modules include quarterly pricing trend reports and regulatory impact analysis.

Differentiator

Problem solved

Functional benefit

Products and services

  • IRA Selection Tool Web-based tool that provides drug-level probabilities of selection for the IRA Drug Price Negotiation Program, including historical changes in those probabilities and quarterly updates to incorporate new policies, guidance, and drug-specific events and sales dynamics. Driven by a proprietary probabilistic prediction framework informed by 100% CMS Part D and Part B spending files, using a bootstrapped model based on a census of Medicare lifecycles. Designed for pharmaceutical brand manufacturers, policymakers, and trade associations assessing direct and indirect IRA impacts.
  • US Prescription Brand Net Pricing Data Tool Web-based platform that incorporates quarterly gross and estimated net pricing data and trends since 2007 for every quarter going forward, covering approximately 1,000 active US brand name prescription drugs across more than 100 companies. Includes WAC-to-net concessions, Medicaid versus non-Medicaid concessions, product roll-up to industry, therapeutic area, and company levels, and both WAC and net prices by year or course of therapy. Delivered via a Tableau Online interface with standardized and customized analyses for manufacturers, trade associations, policymakers, and academic researchers.
  • Quarterly Pricing Trend Reports Individual quarterly reports identifying and assessing positive and negative drivers — by company, therapeutic area, and product — of aggregate net pricing trends, as well as factors influencing pharma market dynamics such as co-pay accumulators and formulary exclusions. Delivered in PDF format within 24 hours of purchase.
  • US Political and Regulatory Analysis Standalone analyses of new and proposed legislation and directives — including the Prescription Drug Pricing Reduction Act (PDPRA), International Pricing Index, Anti-Kickback Statute (AKS) safe harbor rule, and the Inflation Reduction Act — and their industry impact on products, segments, and companies. Available as individual report purchases.

Quantifiable outcome

  • Coverage of approximately 1,000 brand name prescription drugs across more than 100 companies
  • +1 more outcomes

Companies that use SSR Health

Customer profile

Segments4 records

Ideal customer profiles3 records

SSR Health technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature3 records

SSR Health partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

SSR Health competitors and assessment

Company assessment

Broad incumbents

  • Optum (UnitedHealth Group): Optum's health analytics and research divisions provide large-scale claims, prescription, and pricing data to pharma and policymakers. While far broader in scope, it overlaps with SSR Health's Medicare Part D/B spending analysis and policy impact use cases.
  • Wolters Kluwer (Pharma & Regulatory Solutions / Sentinel): Wolters Kluwer offers pharma regulatory and drug-pricing reference data products used by manufacturers and policymakers, comparable to SSR Health's regulatory analysis and pricing data offerings, but as part of a much broader professional information portfolio.
  • IQVIA: IQVIA is the largest global healthcare data and analytics company, offering prescription and commercial datasets (e.g., Xponent, DDD) that overlap with SSR Health's US brand pricing analytics, though IQVIA serves a much broader portfolio of pharma customers.

Emerging players

  • Drug Channels Institute: Drug Channels Institute, founded by Adam Fein, produces influential research and analysis on pharmaceutical pricing, distribution, and rebate dynamics. Its content and insights overlap with SSR Health's thought leadership on gross-to-net pricing and market dynamics.
  • Numerof & Associates: Numerof & Associates is a healthcare strategy consulting firm that helps pharma manufacturers with pricing, market access, and policy impact analysis. It serves a comparable buyer base and addresses overlapping problems with SSR Health's regulatory impact analytics.

Direct peers

  • Norstella (EvaluatePharma): Norstella owns EvaluatePharma and other pharma market intelligence assets that forecast drug sales, pricing, and market access dynamics. Both SSR Health and Norstella serve pharma manufacturers with forecasting and pricing intelligence, though SSR Health is more narrowly focused on net pricing and IRA selection probabilities.
  • Simon-Kucher & Partners: Simon-Kucher is a global consulting firm specializing in pricing, monetization, and market access strategy, with deep pharma pricing expertise. It competes with SSR Health's value proposition of helping manufacturers optimize gross-to-net pricing and contracting.
  • ZS Associates: ZS Associates is a consulting firm with a dedicated pharma pricing, market access, and analytics practice serving brand manufacturers. It overlaps with SSR Health's customer base and use cases around gross-to-net pricing strategy and contracting analytics.
  • Definitive Healthcare: Definitive Healthcare provides commercial intelligence for the healthcare and life sciences industry, including prescription and provider data used for market access decisions. It serves a similar set of manufacturer and consulting buyers as SSR Health.
  • Cencora (formerly AmerisourceBergen / Xcenda): Cencora's consulting arm (formerly Xcenda) provides pharma pricing, market access, and reimbursement analytics to manufacturers, overlapping directly with SSR Health's gross-to-net pricing and policy impact offerings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

SSR Health social profiles

Digital presence

SSR Health financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SSR Health leadership team

Management profile

Number of profiles

Profiles4 records

SSR Health funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SSR Health M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SSR Health

What does SSR Health do?

SSR Health provides US prescription brand drug pricing data and analytics through two primary products: the US Prescription Brand Net Pricing Data Tool, which delivers quarterly gross and estimated net pricing data since 2007 for approximately 1,000 products across 100+ companies, and the IRA Selection Tool, which uses a proprietary probabilistic prediction framework built on 100% CMS Part D and Part B spending files to forecast drug-level odds of selection under the Medicare Drug Price Negotiation Program. Both products are delivered through a Tableau Online web-based interface, complemented by quarterly pricing trend reports and regulatory/political impact analyses.

Is SSR Health a public or private company?

SSR Health is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was SSR Health founded?

SSR Health was founded in 2009. It employs 1 to 10 people.

How does SSR Health make money?

Two revenue lines are on record. Data Subscription Access are the primary driver. The others are individual Report Purchases.

Who are SSR Health's main competitors?

Broad incumbents on record are Optum (UnitedHealth Group), Wolters Kluwer (Pharma & Regulatory Solutions / Sentinel) and IQVIA. Emerging players are Drug Channels Institute and Numerof & Associates. Direct peers are Norstella (EvaluatePharma), Simon-Kucher & Partners, ZS Associates, Definitive Healthcare and Cencora (formerly AmerisourceBergen / Xcenda).

Does SSR Health have an API?

No public API is recorded for SSR Health.

What industry is SSR Health in?

SSR Health's product category is Pharmaceutical Pricing Analytics. Its primary akta.pro industry code is HLAIAKAA, Pricing & Contracting Strategy, with a secondary code of FSAIAGAJ, Medicare Quality, Risk Adjustment & Stars Analytics/Services. Its NAICS code is 541910 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals